What happened
Daehan Nupharm reported separate results for FY2025: revenue of US$139M (+0.1% year on year), operating profit of US$8.03M (−37.2% year on year) and net income of US$10.4M (−1.4% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$139M |
|---|---|
| Revenue vs a year earlier | +0.1% |
| Operating profit | US$8.03M |
| Net income | US$10.4M |
| Period | FY2025 (separate) |
| Filed | 2026-02-05, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260205900630 → open original filing |
Source: DART. Information only, not investment advice.